Strategies and challenges for the next generation of therapeutic antibodies

By A. Beck, T. Wurch, C. Bailly, N. Corvaia. 2010

856 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

OptMAVEn – A New Framework for the de novo Design of Antibody Variable Region Models Targeting Specific Antigen Epitopes (2014, background): “Therapeutic antibodies are widely recognized to be among the most promising agents to treat various diseases, including cancers, immune disorders, and infections [1,2].”
Antibody therapy of cancer (2012, background): “Antibody dose and concentration in the tumour and possible receptor saturation kinetics can also affect theraputic impac”
AbDesign: an algorithm for combinatorial backbone design guided by natural conformations and sequences (2015, methodology): “…methods, such as animal immunization and repertoire selection,33 are capable of isolating binders to target molecules, but there is no general method to target binders to specific epitopes,34,35 hampering efforts to generate specific binders, inhibitors, and allosteric effectors.”
Engineering Phage Host-Range and Suppressing Bacterial Resistance through Phage Tail Fiber Mutagenesis (2019, background): “Similar to phage tail fibers, antibodies are highly selective to their target antigen (Beck et al., 2010; Foltz et al., 2013).”